Rossel L, Moll E
Hospital Psichiatrico, Santiago de Chile.
Acta Psychiatr Scand Suppl. 1990;360:61-2. doi: 10.1111/j.1600-0447.1990.tb05333.x.
Moclobemide and tranylcypromine were compared in 2 randomized groups of 20 depressed patients each. Fifteen of the patients on moclobemide and 18 of those on tranylcypromine were diagnosed as suffering from endogenous depression. The dosage was 150-300 mg moclobemide and 15-30 mg tranylcypromine daily. At the end of treatment, improvement on the Hamilton Rating Scale for Depression was 59.3% in the moclobemide group and 65.5% in the tranylcypromine group. The final overall assessment of efficacy was good or very good for 68% of the patients on moclobemide and for 85% of those on tranylcypromine. The final assessment of tolerance was good or very good for 85% of the moclobemide patients and 100% of the tranylcypromine patients. None of the differences in scores between the groups were statistically significant. This study therefore yielded comparable results for efficacy and tolerance of the 2 drugs in the treatment of depression.
将20名抑郁症患者随机分为两组，分别服用吗氯贝胺和反苯环丙胺。服用吗氯贝胺的患者中有15名、服用反苯环丙胺的患者中有18名被诊断为患有内源性抑郁症。吗氯贝胺的剂量为每日150 - 300毫克，反苯环丙胺的剂量为每日15 - 30毫克。治疗结束时，吗氯贝胺组在汉密尔顿抑郁量表上的改善率为59.3%，反苯环丙胺组为65.5%。对吗氯贝胺组68%的患者和反苯环丙胺组85%的患者的最终总体疗效评估为良好或非常好。对吗氯贝胺组85%的患者和反苯环丙胺组100%的患者的最终耐受性评估为良好或非常好。两组之间的分数差异均无统计学意义。因此，本研究得出了这两种药物在治疗抑郁症方面疗效和耐受性相当的结果。
